Rocket Pharmaceuticals' Kresladi gene therapy has received approval from the US Food and Drug Administration (FDA) for the treatment of rare immune diseases. This approval represents an important step in the treatment of these diseases. Rocket Pharmaceuticals received a priority review voucher due to the approval. The value of this voucher in the secondary market is estimated at approximately 200 million dollars.